GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+1.57%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$320M
AUM Growth
+$320M
(-10%)
Cap. Flow
-$21M
Cap. Flow
% of AUM
-6.58%
Top 10 Holdings %
Top 10 Hldgs %
46.9%
Holding
64
New
14
Increased
9
Reduced
10
Closed
11
Top Buys
| 1 |
RAPT Therapeutics
RAPT
|
$18.1M |
| 2 |
Allogene Therapeutics
ALLO
|
$7.17M |
| 3 |
Galapagos
GLPG
|
$5.17M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
$4.93M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$4.59M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$9.66M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$8.86M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$6.79M |
| 4 |
VistaGen Therapeutics
VTGN
|
$6.75M |
| 5 |
iShares Russell 2000 ETF
IWM
|
$6.63M |
Sector Composition
| 1 | Healthcare | 96.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
RAPT Therapeutics
RAPT
$188M
| $18.1M | 4.98% | +570,000 | New | +$18.1M |
|
2
Ascendis Pharma
ASND
$11.8B
| $17.8M | 4.88% | 135,000 | – | – |
|
3
Fate Therapeutics
FATE
$120M
| $16.1M | 4.41% | 185,000 | – | – |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $15.8M | 4.35% | 850,000 | – | – |
|
5
Arvinas
ARVN
$568M
| $15.8M | 4.34% | 205,000 | – | – |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $15M | 4.13% | 875,000 -300,000 | -26% | -$5.15M |
|
7
Kura Oncology
KURA
$686M
| $14.6M | 4.01% | 700,000 +100,000 | +17% | +$2.09M |
|
8
Cogent Biosciences
COGT
$1.69B
| $13M | 3.57% | 1,600,000 | – | – |
|
|
TRIL
9
DELISTED
Trillium Therapeutics Inc.
TRIL
| $12.1M | 3.33% | 1,250,000 -700,000 | -36% | -$6.79M |
|
10
Iovance Biotherapeutics
IOVA
$807M
| $11.7M | 3.22% | 450,000 -50,000 | -10% | -$1.3M |
|
11
Biogen
BIIB
$19.4B
| $11.3M | 3.09% | 32,500 +12,500 | +63% | +$4.33M |
|
12
Celldex Therapeutics
CLDX
$1.47B
| $9.53M | 2.62% | 285,000 +35,000 | +14% | +$1.17M |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.08M | 2.22% | 50,000 | – | – |
|
|
14
Allogene Therapeutics
ALLO
$251M
| $7.17M | 1.97% | +275,000 | New | +$7.17M |
|
15
TG Therapeutics
TGTX
$4.65B
| $6.98M | 1.92% | 180,000 -20,000 | -10% | -$776K |
|
16
Aldeyra Therapeutics
ALDX
$351M
| $6.8M | 1.87% | 600,000 -50,000 | -8% | -$567K |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $6.54M | 1.8% | 1,000,000 +60,957 | +6% | +$399K |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $6.4M | 1.76% | 350,000 +50,000 | +17% | +$915K |
|
|
STSA
19
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $6.38M | 1.75% | 904,225 | – | – |
|
|
20
VistaGen Therapeutics
VTGN
$102M
| $6.3M | 1.73% | 2,000,000 -2,143,702 | -52% | -$6.75M |
|
21
Mersana Therapeutics
MRSN
$36.5M
| $6.11M | 1.68% | 450,000 | – | – |
|
|
BCYC
22
Bicycle Therapeutics
BCYC
$511M
| $6.07M | 1.67% | 200,000 +50,000 | +33% | +$1.52M |
|
23
ESSA Pharma
EPIX
$11.4M
| $5.93M | 1.63% | 207,500 +32,500 | +19% | +$928K |
|
|
24
Rocket Pharmaceuticals
RCKT
$354M
| $5.54M | 1.52% | 125,000 -200,000 | -62% | -$8.86M |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $5.18M | 1.42% | 500,000 | – | – |
|